A pilot randomized placebo-controlled trial of adjunctive aripiprazole for chronic PTSD in US military Veterans resistant to antidepressant treatment
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Many individuals with post-traumatic stress disorder (PTSD) experience persistent symptoms despite pharmacological treatment with antidepressants. Several open-label monotherapy and adjunctive studies have suggested that aripiprazole (a second-generation antipsychotic) may have clinical utility in PTSD. However, there have been no randomized placebo-controlled trials of aripiprazole use for PTSD. We thus conducted a pilot randomized controlled trial of adjunctive aripiprazole versus placebo among Veterans with chronic PTSD serving in the US military since 11 September 2001 to assess the feasibility, safety, tolerability, and therapeutic potential of aripiprazole. Sixteen Veterans were randomized, and 14 completed at least 4 weeks of the study; 12 completed the entire 8-week trial. Outcome measures included the Clinician-Administered PTSD Scale (CAPS), PTSD Checklist, Beck Depression Inventory, Second Edition, and Positive and Negative Syndrome Scale scores. Aripiprazole was well-tolerated in this cohort, and improvements in CAPS, PTSD Checklist, Beck Depression Inventory, Second Edition, and Positive and Negative Syndrome Scale scores were as hypothesized. Although CAPS change scores did not reach statistical significance, aripiprazole outperformed placebo by 9 points on the CAPS in the last observation carried forward analysis compared with the placebo group (n = 7 per group), and by 20 points in the group randomized to aripiprazole that completed the entire study (n = 5) compared with the placebo group (n = 7). Results suggest promise for aripiprazole as an adjunctive strategy for the treatment of PTSD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Marcus, R. N., McQuade, R. D., Carson, W. H., Hennicken, D., Fava, M., Simon, J. S., Trivedi, M. H., Thase, M. E., & Berman, R. M. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31816774f9 · Cited by 518 · cited 4×
“(iii) Aripiprazole is effective as an augmentation agent in major depression (Marcus et al., 2008; Berman et al., 2009), and depression symptoms frequently co-occur in patients with PTSD (Kessler et al., 1995).”
BackgroundResultInfluentialPharmacologic alternatives to antidepressants in posttraumatic stress disorder: A systematic review
Berger, W., Mendlowicz, M. V., Marques-Portella, C., Kinrys, G., Fontenelle, L. F., Marmar, C. R., & Figueira, I. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.12.004 · Cited by 347 · cited 2×
“A significant percentage of individuals with posttraumatic stress disorder (PTSD) continue to experience persistent symptomatology despite treatment with selective serotonin reuptake inhibitors or other antidepressant medications (Berger et al., 2009).”
BackgroundHeppner, P. S., Crawford, E. F., Haji, U. A., Afari, N., Hauger, R. L., Dashevsky, B. A., Horn, P. S., Nunnink, S. E., & Baker, D. G. (2009) · BMC Medicine · doi:10.1186/1741-7015-7-1 · Cited by 274 · cited 1×
“Given the high rates of metabolic syndrome among patients with PTSD (Heppner et al., 2009), this favorable side-effect profile may be particularly advantageous in this cohort.”
BackgroundBerman, R. M., Fava, M., Thase, M. E., Trivedi, M. H., Swanink, R., McQuade, R. D., Carson, W. H., Adson, D., Taylor, L., Hazel, J., et al. (2009) · CNS Spectrums · doi:10.1017/s1092852900020216 · Cited by 260 · cited 1×
“(iii) Aripiprazole is effective as an augmentation agent in major depression (Marcus et al., 2008; Berman et al., 2009), and depression symptoms frequently co-occur in patients with PTSD (Kessler et al., 1995).”
BackgroundCarey, P., Suliman, S., Ganesan, K., Seedat, S., & Stein, D. J. (2012) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2238 · Cited by 70 · cited 1×
“…et al., 2001; Petty et al., 2001; Pivac et al., 2004; Kozarić-Kovacić et al., 2005; Padala et al., 2006; Pivac and Kozarić-Kovacić, 2006; Kozaric-Kovacic and Pivac, 2007; Carey et al., 2012; please see Table 1 for a comprehensive listing of secondgeneration antipsychotic studies on PTSD).”
Background
Cited by
Lee, D. J., Schnitzlein, C. W., Wolf, J. P., Vythilingam, M., Rasmusson, A. M., & Hoge, C. W. (2016) · Depression and Anxiety · doi:10.1002/da.22511 · Cited by 416
Hoskins, M. D., Bridges, J., Sinnerton, R., Nakamura, A., Underwood, J. F. G., Slater, A., Lee, M. R. D., Clarke, L., Lewis, C., Roberts, N. P., et al. (2021) · European Journal of Psychotraumatology · doi:10.1080/20008198.2020.1802920 · Cited by 127
“…et al., 2002; Jetly et al., 2015; Krystal et al., 2011; Lindley et al., 2007; Ludascher et al., 2015; Manteghi et al., 2014; Monnelly et al., 2003; Naylor et al., 2015; Neylan et al., 2006; Petrakis et al., 2016; Pollack et al., 2011; Ramaswamy et al., 2016; Raskind et al., 2018, 2007, 2003,…”
BackgroundInfluentialImmobility reactions under threat: A contribution to human defensive cascade and PTSD
Volchan, E., Rocha-Rego, V., Bastos, A. F., Oliveira, J. M., Franklin, C., Gleiser, S., Berger, W., Souza, G. G. L., Oliveira, L., David, I. A., et al. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.01.025 · Cited by 87
Albert, U., Carmassi, C., Cosci, F., De Cori, D., Di Nicola, M., Ferrari, S., Poloni, N., Tarricone, I., & Fiorillo, A. (2016) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000127 · Cited by 58
“The only randomized placebocontrolled trial with an aripiprazole add-on yielded negative results (Naylor et al., 2015).”
BackgroundBajor, L. A., Balsara, C., & Osser, D. N. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114840 · Cited by 43
Metadata
- Authors
- Naylor, J. C., Kilts, J. D., Bradford, D. W., Strauss, J. L., Capehart, B. P., Szabo, S. T., Smith, K. D., Dunn, C. E., Conner, K. M., Davidson, J. R. T., Wagner, H. R., Hamer, R. M., & Marx, C. E.
- Venue
- International Clinical Psychopharmacology
- Published
- 2015-05
- Volume
- 30
- Issue
- 3
- Pages
- 167-174
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W1971595028
- Cited by
- 33
- References
- 5
- FWCI
- 5.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A pilot randomized placebo-controlled trial of adjunctive aripiprazole for chronic PTSD in US military Veterans resistant to antidepressant treatment. https://app.cochat.ai/papers/10.1097/yic.0000000000000061
- The paper
- Naylor, J. C., Kilts, J. D., Bradford, D. W., Strauss, J. L., Capehart, B. P., Szabo, S. T., Smith, K. D., Dunn, C. E., Conner, K. M., Davidson, J. R. T., Wagner, H. R., Hamer, R. M., & Marx, C. E. (2015). A pilot randomized placebo-controlled trial of adjunctive aripiprazole for chronic PTSD in US military Veterans resistant to antidepressant treatment. International Clinical Psychopharmacology. https://doi.org/10.1097/yic.0000000000000061
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.